Harbin Medisan Pharmaceutical Co., Ltd.

002900

CNE1000032V9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
9.87 ^CNY	-1.60%		-19.69%	-27.69%

Apr. 26	Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	MT
Apr. 25	Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020

May 19, 2021 at 03:35 pm EDT

Harbin Medisan Pharmaceutical Co., Ltd. approved a final cash dividend per ten shares (tax included) of CNY 0.80000000 for the year 2020.

Latest news about Harbin Medisan Pharmaceutical Co., Ltd.

Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	Apr. 26	MT
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Harbin Medisan Pharma Gets Patent Rights of China Pharmaceutical University-Developed Drug	23-05-04	MT
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Management Appointments	22-11-28	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-29	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	21-04-27	CI
Harbin Fuerjia Technology Development Co., Ltd. completed the acquisition of Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd..	21-02-28	CI
Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. for CNY 570 million.	21-02-09	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-22	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-23	CI
Tranche Update on Harbin Medisan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 31, 2019.	20-01-09	CI
Harbin Medisan Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 31, 2019, has expired with 6,815,183 shares, representing 2.15% for CNY 87.17 million.	20-01-07	CI
Tranche Update on Harbin Medisan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 31, 2019.	20-01-02	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Election of Directors	19-12-19	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019	19-10-23	CI
Tranche Update on Harbin Medisan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 31, 2019.	19-10-09	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-22	CI

Chart Harbin Medisan Pharmaceutical Co., Ltd.

Duration

Period

Chart Harbin Medisan Pharmaceutical Co., Ltd.

More charts

HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARBIN MEDISAN PHARMACEUTICAL CO., LTD.	-27.69%	429M
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B